SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis

Authors:

Abstract
COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. In this study, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor through the upregulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. This new evidence pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target. Key Points T cells from COVID-19 patients display less complex N-glycans at diagnosis. IL-2 is a putative driver of glycan switch in COVID-19 patients. DC-SIGN expression in monocytes at diagnosis predicts poor disease course.
All Related Versions
Funding Information
  • MEC | Fundação para a Ciência e a Tecnologia (Project #6 RESEARCH 4 COVID)
  • MEC | Fundação para a Ciência e a Tecnologia (SFRH/BD/128874/2017)
  • MEC | Fundação para a Ciência e a Tecnologia (PD/BD/135452/2017)

This publication has 29 references indexed in Scilit: